Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

Nature Medicine

Volumn 6, Issue 9, 2000, Pages 1018-1023

  Molldrem, Jeffrey J ^a   Lee, Peter P ^b   Wang, Changqing ^a   Felio, Kyrie ^a   Kantarjian, Hagop M ^a   Champlin, Richard E ^a   Davis, Mark M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; LEUKEMIA ANTIGEN; LEUKOCYTE ANTIGEN; MYELOBLASTIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUMOR IMMUNITY;

BLOOD CIRCULATION; BONE MARROW TRANSPLANTATION; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS LEUKEMIA EFFECT; HUMAN; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; PEPTIDE FRAGMENTS; REMISSION INDUCTION; SERINE ENDOPEPTIDASES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033826799     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/79526     Document Type: Article

References (29)

1. Konstantinidou, P., Szydlo, R.M., Chase, A. & Goldman, J.M. Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant 25, 143-146 (2000).
2. McGlave, P. Unrelated donor transplant therapy for chronic myelogenous leukemia. Hematol. Oncol. Clin. North Am. 12, 93-105 (1998).
3. Collins, R.H., Jr. et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15, 433-444 (1997).
4. Kolb, H.J. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86, 2041-2050 (1995).
5. van Rhee, F., Lin, F., Cullis, J.O. & Goldman, J. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor lymphocyte transfusions before the onset of hematological relapse. Blood 83, 3377-3383 (1994).
6. Faderl, S., Talpaz, M., Estrov, Z. & Kantarjian, H.M. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. 131, 207-219 (1999).
7. Dowding, C., Guo, A.P., Maisin, D., Gordon, M.Y. & Goldman, J.M. The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint. Br. J. Haematol. 77, 165-171 (1991).
8. Gordon, M.Y. et al. Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J. Clin. Invest. 102, 710-715 (1998).
9. den Haan, J.M. et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279, 1054-1057 (1998).
10. den Haan, J.M.M. et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268, 1476-1480 (1995).
11. Marijt, W.A. et al. Minor histocompatibility antigens HA-1, -2, and -4, and HY-specific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact. Blood 82, 3778-3785 (1995).
12. Goulmy, E. et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334, 281-285 (1996).
13. Falkenburg, J.H. et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94, 1201-1208 (1999).
14. Childs, R., Epperson, D., Bahceci, E., Clave, E. & Barrett, J. Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. Br. J. Haematol. 107, 396-400 (1999).
15. Dengler, R. et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br. J. Haematol. 89, 250-257 (1995).
16. Bories, D., Raynal, M.C., Solomon, D.H., Darzynkiewicz, Z. & Cayre, Y.E. Down-regulation of a serine protease, myeloblastin, causes gwoth arrest and differentiation of promyelocytic leukemia cells. Cell 59, 959 (1989).
17. Molldrem, J. et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88, 2450-2457 (1996).
18. Molldrem, J.J. et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90, 2529-2534 (1997).
19. Molldrem, J.J., Lee, P.P., Wang, C., Champlin, R.E. & Davis, M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59, 2675-2681 (1999).
20. Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
21. Lee, P.P. et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med. 5, 677-685 (1999).
22. Greiner, J.W. et al. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res. 44, 3208-3214 (1984).
23. Natali, P.G. et al. Molecular profile, tissue distribution and prognostic evaluation of a human melanoma-carcinoma antigen recognized by the murine monoclonal antibody B1.1. Int. J. Biol. Markers 3, 211-220 (1988).
24. Dermime, S. et al. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 19, 989-999 (1997).
25. Faber, L.M. et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J. Clin. Invest. 96, 877-883 (1995).
26. McLaughlin-Taylor, E. et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J. Med. Virol. 43, 103-110 (1994).
27. Riddell, S.R. & Greenberg, P.D. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13, 545-586 (1995).
28. Salter, R.D. & Cresswell, P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. Embo. J. 5, 943-949 (1986).
29. Anderson, K. et al. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I- restricted cell-mediated lysis. J. Exp. Med. 174, 489-492 (1991).